Clinical trials: Stage 2 Hypertension
Endothelial Dysfunction
A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction
This Phase 2, randomized, open-label, 2-treatment, 2-sequence, 2-period crossover, pharmacokinetic (PK) study will compare plasma concentrations of BH4 in subjects with endothelial dysfunction following 14 days of treatment by…
- Trial name
- NCT00532844
- Testing
- Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- BioMarin Pharmaceutical
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98
The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after twelve months of treatment in Japanese subjects.
- Trial name
- NCT00047593
- Testing
- IOP Lowering Medications
- Where
- 3 sites in United States
- Sponsor
- Alcon Research
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
- Trial name
- NCT07123779
- Testing
- HS235
- Where
- 3 sites in United States
- Volunteers
- 126 people
- Sponsor
- 35Pharma Inc., a GSK company
Hypertension,Essential
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.
- Trial name
- NCT04218552
- Testing
- AD209, Amlodipine low, Amlodipine high
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Addpharma Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329
This study will characterize the effect of PF-04217329, alone and in combination with latanoprost, on circadian intraocular pressure and blood pressure in glaucoma patients.
- Trial name
- NCT00934089
- Testing
- PF-04217329, latanoprost vehicle, latanoprost
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension
Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged.
- Trial name
- APPROACH-2 (NCT04915300)
- Testing
- Apabetalone
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Laval University
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Glaucoma, Ocular Hypertension
A Study of Different Formulations of the L-PPDS in Subjects With OH or OAG
The purpose of this study is to evaluate the safety and preliminary efficacy of two formulations of the Latanoprost-PPDS in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00967811
- Testing
- Formulation E1 of L-PPDS, Formulation E2 of L-PPDS
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Mati Therapeutics Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, compared to…
- Trial name
- NCT06964191
- Testing
- PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- PolyActiva Pty Ltd
Hypertension, COVID-19
ARB, ACEi, DRi Effects on COVID-19 Course Disease
It is supposed to monitor hypertensive patients who are infected or have clinical manifestations of COVID-19 for 1 month after the onset of the disease. Three groups will be considered: 1. receiving ACE inhibitors 2.
- Trial name
- BIRCOV (NCT04364984)
- Testing
- Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, Direct renin inhibitor
- Where
- Ukraine
- Volunteers
- 112 people
- Sponsor
- Medical Practice Prof D. Ivanov
Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1/2, randomized, double-blind, placebo-controlled, first-in-human study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of subcutaneously administered DIAG723 in adult patients with…
- Trial name
- DIAMOND (NCT07623525)
- Testing
- DIAG723
- Where
- 11 sites in Australia, Canada and 1 more
- Volunteers
- 93 people
- Sponsor
- Diagonal Therapeutics, Inc.
Primary Open Angle Glaucoma
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
- Trial name
- NCT06223048
- Testing
- AMDX-2011P
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Amydis Inc.
Essential Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of BR1015 and co-administration of BR1015-3 and BR1015-2 in healthy volunteers under fasting conditions
- Trial name
- NCT06744426
- Testing
- BR1015, BR1015-2, BR1015-3
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1015" and co-administration of "BR1015-1" and "BR1015-2" under fed conditions in healthy volunteers
- Trial name
- NCT06008015
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pulmonary Arterial Hypertension
Drug Interaction Between Ritonavir And Sitaxsentan
The study is to assess if sitaxsentan and ritonavir will affect the blood levels of each other when coadministered.
- Trial name
- NCT01251848
- Testing
- Sitaxentan, Ritonavir, Sitaxsentan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Stage 2 Hypertension
8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension
To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
- Trial name
- VANTAGE (NCT00809926)
- Testing
- Valsartan/aliskiren, Valsartan
- Where
- United States
- Volunteers
- 451 people
- Sponsor
- Novartis
Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)
This is a randomized, double-blind, multi-center, placebo-controlled dose-ranging clinical trial of two IkT-001Pro doses in patients with PAH designed to assess safety, tolerability and efficacy.
- Trial name
- NCT06643143
- Testing
- IkT-001Pro
- Sponsor
- Inhibikase Therapeutics
Hypertension
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
This study will evaluate the efficacy of valsartan/hydrochlorothiazide versus amlodipine and hydrochlorothiazide in patients with Stage 2 hypertension using 24-hr ambulatory blood pressure monitoring (ABPM)
- Trial name
- NCT00425997
- Testing
- Valsartan/HCTZ, amlodipine, HCTZ
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Novartis
Ocular Hypertension, Open Angle Glaucoma
A Study Evaluating the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to test if latanoprost punctal plugs will reduce eye pressure in subjects with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT01229982
- Testing
- Latanoprost-PPDS
- Where
- Canada
- Volunteers
- 121 people
- Sponsor
- Mati Therapeutics Inc.
Hypertension
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of an amlodipine/losartan combination treatment and amlodipine monotherapy for treatment of Stage 2 hypertensive patients.
- Trial name
- NCT01127217
- Testing
- amlodipine/losartan, amlodipine
- Where
- South Korea
- Volunteers
- 149 people
- Sponsor
- Hanmi Pharmaceutical Company Limited